Vistagen Therapeutics, Inc. - Common Stock (VTGN)

Q3 2023 13F Holders as of 9/30/2023

Type / Class
Equity / Common Stock
Shares outstanding
30.6M
Number of holders
34
Total 13F shares, excl. options
3M
Shares change
+1.81M
Total reported value, excl. options
$15.7M
Value change
+$10.1M
Put/Call ratio
0.27
Number of buys
23
Number of sells
-16
Price
$5.24

Significant Holders of Vistagen Therapeutics, Inc. - Common Stock (VTGN) as of Q3 2023

47 filings reported holding VTGN - Vistagen Therapeutics, Inc. - Common Stock as of Q3 2023.
Vistagen Therapeutics, Inc. - Common Stock (VTGN) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3M shares of 30.6M outstanding shares and own 9.81% of the company stock.
Largest 10 shareholders include COMMODORE CAPITAL LP (1.58M shares), VANGUARD GROUP INC (254K shares), Ikarian Capital, LLC (229K shares), Schonfeld Strategic Advisors LLC (139K shares), SPHERA FUNDS MANAGEMENT LTD. (100K shares), BML Capital Management, LLC (100K shares), BlackRock Inc. (88K shares), BLAIR WILLIAM & CO/IL (85.2K shares), GROUP ONE TRADING, L.P. (75.3K shares), and GEODE CAPITAL MANAGEMENT, LLC (73.2K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.